Updated Jul 16, 2026
Klein Matthew B. has filed 4 SEC Form 4 filings across 2 companies in the last 90 days — selling. Lifetime open-market sales: $3.50M.
Matthew B. Klein is the Chief Executive Officer of PTC Therapeutics, Inc., a biopharmaceutical company focused on developing treatments for rare disorders. He has been involved in multiple SEC filings related to his role at the company.
| Role | Insider |
|---|---|
| Notability | 30/100 |
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-05-26 | CLPT | ClearPoint Neuro, Inc. | S — Open-market sale | 16.0K | $11.59 | $185K |
| 2026-05-21 | CLPT | ClearPoint Neuro, Inc. | M — Option exercise | 12.4K | — | |
| 2026-05-15 | PTCT | PTC THERAPEUTICS, INC. | S — Open-market sale | 2.6K | $72.46 | $186K |
| 2026-05-15 | PTCT | PTC THERAPEUTICS, INC. | S — Open-market sale | 2.1K | $73.08 | $153K |
| 2026-05-15 | PTCT | PTC THERAPEUTICS, INC. | S — Open-market sale | 7.2K | $73.08 | $528K |
| 2026-05-15 | PTCT | PTC THERAPEUTICS, INC. | S — Open-market sale | 679 | $73.06 | $50K |
| 2026-05-15 | PTCT | PTC THERAPEUTICS, INC. | A — Grant or award | 12.5K | $0.00 | |
| 2026-04-23 | PTCT | PTC THERAPEUTICS, INC. | S — Open-market sale | 2.9K | $70.91 | $202K |
| 2026-03-13 | PTCT | PTC THERAPEUTICS, INC. | S — Open-market sale | 2.7K | $64.08 | $171K |
| 2026-03-13 | PTCT | PTC THERAPEUTICS, INC. | A — Grant or award | 12.5K | $0.00 | |
| 2026-02-20 | PTCT | PTC THERAPEUTICS, INC. | S — Open-market sale | 7.4K | $69.36 | $511K |
| 2026-01-12 | PTCT | PTC THERAPEUTICS, INC. | S — Open-market sale | 2.5K | $76.45 | $192K |
| 2026-01-08 | PTCT | PTC THERAPEUTICS, INC. | S — Open-market sale | 3.0K | $77.48 | $234K |
| 2026-01-08 | PTCT | PTC THERAPEUTICS, INC. | S — Open-market sale | 5.1K | $76.95 | $396K |
| 2025-08-01 | PTCT | PTC THERAPEUTICS, INC. | S — Open-market sale | 10.7K | $51.74 | $556K |
| 2025-08-01 | PTCT | PTC THERAPEUTICS, INC. | A — Grant or award | 75.0K | $0.00 | |
| 2025-05-16 | CLPT | ClearPoint Neuro, Inc. | M — Option exercise | 21.1K | — | |
| 2025-04-22 | PTCT | PTC THERAPEUTICS, INC. | S — Open-market sale | 2.8K | $48.74 | $137K |
Matthew B. Klein is the Chief Executive Officer of PTC Therapeutics, Inc., a biopharmaceutical company focused on developing treatments for rare disorders. He has been involved in multiple SEC filings related to his role at the company.…
4 primary Form 4 filings in the last 90 days, covering 2 companies.
Recorded transactions: 0 open-market purchases () and 13 open-market sales ($3.50M) across all tracked filings.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live Klein Matthew B. profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.